Sensitivity to synthetic aromacyclic amino spirits of Candida isolated in the patients with type i diabetes
DOI:
https://doi.org/10.32402/dovkil2020.01.039Keywords:
candidiasis, Candida, amino spirits, itraconazole, fluconazole, amphotericin BAbstract
The derivatives of aromatic amino spirits are a promising group of the substances with antimycotic effect. Objective: The aim of the study was to investigate the sensitivity of clinical isolates of yeast-like fungi of Candida genus, obtained from oral subbiotopes of the patients with type I diabetes, to synthetic aromacyclic amino spirits and commercial antimycotics. Materials and methods: We applied the bibliosemantic, microscopic, mycological, statistical and analytical methods in the study. Results and discussion: 90 isolates of the representatives of Candida genus were isolated. The frequency of the isolation of yeast fungi in the oral biotope made up 66.1%. The level of oral candidiasis among patients with type I diabetes was 5.1%. C.albicans, C. glabrata, C. krusei, C. tropicalis, С. kefyr were indicated in the subbiotopes of oral cavity among the representatives of Candida genus, C. Albicans takes 67.8% , C. Glabrata - 10.0% , 16 , C. Krusei - 7% -, C. Tropicalis – 3.3%, S. kefyr - 2,2%. Among the compounds, Kc22 had the highest activity, which, at the concentration of 0.24-0.97 µg / ml, inhibited 59.0% of the strains. Amphotericin B showed the highest activity among commercial antimycotics. Fluconazole and intraconazole were ineffective against clinical strains. Conclusions: The frequency of the isolation of yeast fungi in the oral biotope in the patients with type I diabetes made up 66.2%. C. albicans is a predominant candid in all studied oral subbiotopes (67.8%). Clinical isolates are resistant to itraconazole (100%) and fluconazole (81.7%). All isolates were sensitive to amphotericin B (75.3%). Alkyl (aryloxyethoxy) dialkyl-aminopropanol derivatives had high anticandidous activity against all types of clinical isolates.Downloads
References
1. Rodrigues C., Rodrigues M., Henriques M. Candida sp. Infections in Patients with Diabetes Mellitus. Journal of Clinical Medicine. 2019. Vol. 8 (1). 76. DOI : https://doi.org/10.3390/jcm8010076
2. Karaa A., Goldstein A. The spectrum of clinical presentation, diagnosis, and management of mitochondrial forms of diabetes. Pediatric Diabetes. 2015. Vol. 16 (1). 1–9. DOI : https://doi.org/10.1111/pedi.12223
3. King H., Aubert R., Herman W. Global burden of diabetes, 1995-2025: Prevalence, numerical estimates, and projections. Diabetes Care. 1998. Vol. 21 (9). 1414–1431. DOI : https://doi.org/10.2337/diacare.21.9.1414
4. Agarwal S., Raman R., Paul P., Rani P., Uthra S., Gayathree R., McCarty C. et al. Sankara Nethralaya—Diabetic Retinopathy Epidemiology and Molecular Genetic Study (SN—DREAMS 1): Study Design and Research Methodology. Ophthalmic Epidemiology. 2005. Vol. 12 (2). P. 143–153. DOI : https://doi.org/10.1080/09286580590932734
5. Guimarães T., Nucci M., Mendonça J., Martinez R., Brito L., Silva N., Moretti M. et al. Epidemiology and predictors of a poor outcome in elderly patients with candidemia. International Journal of Infectious Diseases. 2012. Vol.16 (6). P. 442–447. DOI : https://doi.org/10.1016/j.ijid.2012.02.005
6. Khosravi A., Yarahmadi S., Baiat M., Shokri H., Pourkabireh M. Factors affecting the prevalence of yeasts in the oral cavity of patients with diabetes mellitus. Journal de Mycologie Médicale. 2008. Vol. 18 (2). P. 83–88. DOI : https://doi.org/10.1016/j.mycmed.2008.04.002
7. Tang H., Liu W., Lin H., Lai C. Epidemiology and prognostic factors of candidemia in elderly patients. Geriatrics Gerontologie International. 2015. Vol. 15 (6). P. 688–693. DOI : https://doi.org/10.1111/ggi.12329
8. Belazi M., Velegraki A., Fleva A., Gidarakou I., Papanaum L., Baka D. et al. Candidal overgrowth in diabetic patients: Potential predisposing factors. Mycoses. 2005. Vol. 48 (3). P. 192–196. DOI : https://doi.org/10.1111/j.1439-0507.2005.01124.x
9. Gonçalves R., Miranda E., Zaia J., Giannini M. Species diversity of yeast in oral colonization of insulin-treated diabetes mellitus patients. Mycopathologia. 2006. Vol. 162 (2). P. 83–89. DOI : https://doi.org/10.1007/s11046-006-0038-5
10. Левицький А.П., Ніколишин А.К, Ступак О.П., Ступак П.П. Кандидоз слизової порожнини рота у хворих на цукровий діабет типу 1: клініка, діагностика, лікування, профілактика. Український стоматологічний альманах. 2010. T. 2, №2. С. 22-26.
11. Wiederhold N., Tam V., Chi J., Prince R., Kontoyiannis D., Lewis R. Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis. Antimicrobial Agents and Chemotherapie. 2006. Vol. 50 (2). P. 469-473. DOI : https://doi.org/10.1128/AAC.50.2.469-473.2006
12. Berkow E., Lockhart S. Fluconazole resistance in Candida species: a current perspective. Infection and Drug Resistance. 2017. V0l. 10. P. 237–245. DOI : https://doi.org/10.2147/IDR.S118892
13. Kondoh O., Inagaki Y., Fukuda H., Mizuguchi E., Ohya Y., Arisawa M., Shimma N. et al. Piperazine propanol derivative as a novel antifungal targeting 1,3-b -d-glucan synthase. Biological and Pharmaceutical Bulletin. 2005. Vol. 8 (11). P. 2138—2141. DOI : https://doi.org/10.1248/bpb.28.2138
14. Arendrup M., Cuenca-Estrella M., Lass-Florl C., Hope W. EUCAST technical note on the EUCAST definitive document EDef 7.2: Method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST). Clinical Microbiologie and Infection. 2012. Vol. 18 (7). P. 246-247. DOI : https://doi.org/10.1111/j.1469-0691.2012.03880.x
Downloads
Published
Issue
Section
License
Copyright (c) 2020 Environment & Health
This work is licensed under a Creative Commons Attribution 4.0 International License.
